市场调查报告书
商品编码
1354344
血液检测市场规模 - 按测试类型、按产品、按方法、按最终用途、2023 - 2032 年全球预测Blood Testing Market Size - By Test Type, By Product, By Method, By End-use, Global Forecast 2023 - 2032 |
由于 COVID-19 大流行期间对全血细胞计数 (CBC) 检测的需求激增,血液检测市场规模预计在 2023 年至 2032 年期间复合年增长率为 6.7%。
事实证明,CBC 测试对于确定患者的整体健康状况和识别可能的感染至关重要,从而导致其在医疗保健中越来越多地采用血液诊断。随着COVID-19患者数量的不断增加,人们越来越担心週边血球会发生实质变化,例如淋巴球减少和嗜中性球增多。根据先前披露的资料,儘管劳动力短缺,安大略省的诊断实验室在 2021 年 12 月每天仍进行约 50,000 次检测。事实证明,COVID-19 患者对 CBC 检测的需求不断增加,有利于行业增长。
整个血液检测市场根据检测类型、产品、方法、最终用途和地区进行细分。
就检测类型而言,预计到2032年,传染病筛检领域的血液检测市场规模将呈现强劲增长。血液检测对于早期识别和诊断新的传染病(例如SARS、登革热、莱姆病)是必要的。 、尼帕病毒脑炎等。除了诊断技术的发展之外,此类传染病的高盛行率也将推动该细分市场的扩张。例如,2022 年 5 月,Becton, Dickinson, and Company 在美国推出了其创新的全自动传染病分子诊断平台
就最终用途而言,预计从2023 年到2032 年,病理学领域的血液检测市场价值将以显着的复合年增长率增长。各种传染性和非传染性疾病的发病率不断上升,例如癌症、心血管疾病、胃肠道疾病、肾臟疾病和泌尿系统困难导致需要对这些疾病进行有效的诊断和治疗。随着医疗保健系统优先考虑预防保健和个人化医疗,病理实验室有望处于诊断和筛检服务的最前线。
从地区来看,欧洲在2022 年占据了血液检测市场的相当大份额,并将在2032 年之前实现大幅增长。老年人口基数的增加以及糖尿病及其相关併发症的大量流行将提高该地区的血液检测率。根据欧洲议会在 2022 年世界糖尿病日提出的估计,欧盟有超过 3,200 万人患有糖尿病。此外,严格的医疗保健法规和对预防保健的关注导致诊断服务的采用率更高。血液检测技术的不断创新和对研发活动的更大投入也将有助于市场成长。
Blood Testing Market size is poised to depict 6.7% CAGR from 2023-2032 driven by the surging demand for complete blood count (CBC) tests during the COVID-19 pandemic.
CBC tests have proven essential in determining the general health of patients and identifying possible infections, leading to their increased adoption for blood diagnostics in healthcare. With the rising count of COVID-19 patients, the growing concerns of substantial changes in peripheral blood cells, such as lymphopenia and neutrophilia significantly soared. According to previously disclosed data, despite the workforce shortage, diagnostic laboratories in Ontario conducted about 50,000 tests each day in December 2021. This increasing demand for CBC tests among COVID-19 patients proved favorable for the industry growth.
The overall blood testing market is segmented based on test type, product, method, end-use, and region.
With respect to test type, the blood testing market size from the infectious disease screening segment is estimated to depict robust growth through 2032. Blood testing is necessary for the early identification and diagnosis of new infectious illnesses, such as SARS, dengue fever, Lyme disease, Nipah virus encephalitis, and others. The high prevalence of such infectious illnesses, in addition to the developments in diagnostic technology, will drive the segment expansion. For instance, in May 2022, Becton, Dickinson, and Company launched its innovative, fully automated infectious disease molecular diagnostics platform in the U.S.
In terms of end-use, the blood testing market value from the pathology segment is estimated to expand at notable CAGR from 2023 to 2032. The growing incidence of various communicable and non-communicable diseases, such as cancer, cardiovascular disease, gastrointestinal disorders, renal disorders, and urological difficulties have resulted in the need for effective diagnosis and treatment of the diseases. With healthcare systems prioritizing preventive care and personalized medicine, pathology laboratories are expected to be at the forefront of diagnostic and screening services.
Regionally, Europe held sizable share of the blood testing market in 2022 and is set to record substantial growth through 2032. The rising geriatric population base and the substantial prevalence of diabetes along with complications related to it will increase the rate of blood testing regionally. According to estimations presented by the European Parliament on World Diabetes Day 2022, over 32 million individuals in the EU suffer from diabetes. Moreover, the stringent healthcare regulations and the focus on preventive care is leading to the higher adoption of diagnostic services. Increasing innovations in blood testing technologies and the higher commitment to R&D activities will also contribute to the market growth.